CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone

Journal of Bone and Mineral Research

Volumn 24, Issue 1, 2009, Pages 70-77

  Forsyth, Ramses G ^a   De Boeck, Gitte ^a   Baelde, Johannes J ^b   Taminiau, Anthonie H M ^b   Uyttendaele, Dirk ^a   Roels, Hendrik ^a   Praet, Marleen M ^a   Hogendoorn, Pancras C W ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; CD14; CD33; Giant cell tumor; Osteoclast

Indexed keywords

CD14 ANTIGEN; CD33 ANTIGEN; CD51 ANTIGEN; MONOCLONAL ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE TUMOR; CELL POPULATION; CLINICAL ARTICLE; FEMALE; GIANT CELL TUMOR; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MALE; MONONUCLEAR CELL; MULTINUCLEAR CELL; OSTEOCLAST; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE NEOPLASMS; FEMALE; GIANT CELL TUMORS; HUMANS; INTEGRIN ALPHAV; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOCLASTS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 58149092512     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080905     Document Type: Article

References (33)

1. Reed R, Banerjee SS, Sciot R 2002 Giant cell tumour. In: Fletcher CD, Unni KK, Mertens F (eds.) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, France, pp. 310-312.
2. Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, Verheijen JH, Hogendoom PC 2004 CathepsinK is the principal protease in giant cell tumor of bone. Am J Pathol 165:593-600.
3. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM 2001 The histogenesis of giant cell tumour of bone: A model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 16:297-307.
4. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N 2005 Phenotypic and molecular studies of giant-cell tumours of bone and soft tissue. Hum Pathol 36:945-954.
5. Forsyth RG, De Boeck G, Bekaert S, De Meyer T, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC 2007 Telomere biology in giant cell tumour of bone. J Pathol. Published on line December 10, 2007.
6. Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine Ta, Parisien MV, Kim W, Winchester RJ, Lee FY 2005 Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 23:203-209.
7. Nicholson GC, Malakellis M, Collier FM, Cameron PU, Holloway WR, Gough TJ, Gregorio-King C, Kirkland MA, Myers DE 2000 Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL). Clin Sci 99:133-140.
8. + monocytes that develop with RANKL into functional osteoclasts. J Bone Miner Res 21:193-206.
9. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA 1996 The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060.
10. Athanasou NA, Quinn J 1990 Immunophenotypic differences between osteoclasts and macrophage polykaryons: Immunohistochemical distinction and implications for osteoclast ontogeny and function. J Clin Pathol 43:997-1003.
11. Massey HM, Flanagan AM 1999 Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 106:167-170.
12. Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P 2002 c-myc is required for osteoclast differentiation. J Bone Miner Res 17:763-773.
13. Hopwood B, Tsykin A, Findlay DM, Fazzalari NL 2007 Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-β/bone morphogenic protein signaling. Arthrit Res Ther 9(5):R100.
14. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J, Fridman WH, Mueller CG, Molina TJ 2006 CD14 and CD169 expression in human lymph nodes and spleen: Specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol 37:68-77.
15. Shalhoub V, Elliot G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle WJ, Lacey DL 2000 Characterization of osteoclast precursors in human blood. Br J Haematol 111:501-512.
16. Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, Jung KC, Kim HS, Park S, Kim HJ, Park MH, Min CK, Kim CC, Park SH 2001 Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol 158:1473-1480.
17. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J, Navarro JL, San Miguel JF 1996 Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: Identification and enumeration. Am J Pathol 149:1493-1499.
18. Best-Aguilera CR, Vazquez-Del Mercado M, Muñoz-Valle JF, Herrera-Zarate L, Navarro-Hernandez RE, Martin-Marquez BT, Oregon-Romero E, Ruiz-Quezada S, Bonilla GM, Lomeli-Guerrero A 2005 Massive myeloid sarcoma affecting the central nervous system, mediastinum, retroperitoneum, liver, and rectum associated with acute myeloblasts leukemia: A case report. J Clin Pathol 58:325-327.
19. Shankar G, Davison I, Helfrich MH, Mason WT, Horton MA 1993 Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts. J Cell Sci 105:61-68.
20. Grano M, Colucci S, De Bellis M, Zigrino P, Argentino L, Zambonin G, Serra M, Scotlandi K, Teti A, Zambonin A 1994 New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. J Bone Miner Res 9:1013-1020.
21. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X 2002 RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 117:210-216.
22. Naoyuki T, Nobuyuki U, Masamichi T, Tatsuo S 2002 Cells of bone: Osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology, 2nd ed. Academic Press, San Diego, CA, USA, pp. 109-139.
23. Quinn JMW, Neale S, Fujikawa Y, McGee JOD, Athanasou NA 1998 Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calcif Tissue Int 62:527-531.
24. Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N 2006 Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthrit Res Ther 8(5):R152.
25. Freeman SD, Kelm S, Barber EK, Crocker PR 1995 Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85:2005-2012.
26. Illes T, Fischer J, Szabo G 1999 Lectin histochemistry of pathological bones. Bull Hosp Jt Dis 58:206-211.
27. Takahata M, Iwasaki N, Nakagawa H, Abe Y, Watanabe T, Ito M, Majima T, Minami A 2007 Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 41:77-86.
28. Brinkman-Van der Linden ECM, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A 2003 CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol 23:4199-4206.
29. Lock K, Zhang J, Lu J, Hee Lee S, Crocker PR 2004 Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 209:199-207.
30. Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kindermann W, Schmitz G 1996 Peripheral blood mononucelar phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 16:1437-1447.
31. Starkie RL, Angus DJ, Rolland J, Hargreaves M, Febbraio MA 2000 Effect of prolonged, submaximal exercise and carbohydrate ingestion on monocytes intracellular cytokine production in humans. J Physiol 528:647-655.
32. Fenton C, Perry CM 2006 Spotlight on gemtuzumab ozogamicin in acute myeloid leukemia. BioDrugs 20:137-139.
33. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR 2005 Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452.